Ensysce Biosciences (ENSC) Retained Earnings (2017 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Retained Earnings of $142.9 million for Q4 2025, up 7.26% year-over-year from $133.3 million in Q4 2024, and up 204.37% quarter-over-quarter from -$137.0 million in Q3 2025.
Ensysce Biosciences (ENSC) Retained Earnings (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Retained Earnings for 9 consecutive years, with $142.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings rose 7.26% year-over-year to $142.9 million; the TTM figure through Dec 2025 stood at $142.9 million (up 7.26% YoY), while the FY2025 annual figure was $142.9 million, up 7.26% from the prior year.
- Retained Earnings climbed to $142.9 million in Q4 2025 per ENSC's latest filing, from -$137.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $142.9 million in Q4 2025 and bottomed at -$137.0 million in Q3 2025.
- Historically, Retained Earnings has averaged $3.3 million across 5 years, with a median of -$30.4 million in 2021.
- Annual changes were most pronounced in 2021 — Retained Earnings plunged 5052.51% — and 2022, when it soared 3145.27%.
- Ensysce Biosciences' Retained Earnings stood at -$85.8 million in 2021, then soared by 224.89% to $107.2 million in 2022, then tumbled by 213.38% to -$121.6 million in 2023, then soared by 209.62% to $133.3 million in 2024, then gained by 7.26% to $142.9 million in 2025.
- Business Quant data shows ENSC's Retained Earnings at $142.9 million in Q4 2025, -$137.0 million in Q3 2025, and $136.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | 142.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 142.93 Mn |
| Sep 30, 2025 | -136.95 Mn |
| Jun 30, 2025 | 136.61 Mn |
| Mar 31, 2025 | -131.49 Mn |
| Dec 31, 2024 | 133.25 Mn |
| Sep 30, 2024 | 132.89 Mn |
| Jun 30, 2024 | 128.45 Mn |
| Mar 31, 2024 | 128.42 Mn |
| Dec 31, 2023 | -121.56 Mn |
| Sep 30, 2023 | -118.05 Mn |
| Jun 30, 2023 | -115.36 Mn |
| Mar 31, 2023 | 113.29 Mn |
| Dec 31, 2022 | 107.22 Mn |
| Sep 30, 2022 | -105.41 Mn |
| Jun 30, 2022 | -95.51 Mn |
| Mar 31, 2022 | 88.90 Mn |
| Dec 31, 2021 | -85.85 Mn |
| Sep 30, 2021 | -75.00 Mn |
| Jun 30, 2021 | -57.84 Mn |
| Mar 31, 2021 | -2.92 Mn |